Vaults as Nonviral Nucleic Acid Delivery Vehicles

Vault 作为非病毒核酸递送载体

基本信息

  • 批准号:
    7365241
  • 负责人:
  • 金额:
    $ 32.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-05-01 至 2010-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Gene therapy requires affordable, scaleable technology for the specific delivery of a gene of interest to the nuclear compartment of a target cell without triggering an immune response. Although viral and nonviral vectors have been designed to deliver DNA to cells, interest in nonviral vectors has grown from the promise that they can overcome numerous limitations inherent in manipulating viruses including their complexity, difficulty to adapt to large-scale production and ease of triggering an immune response. The nonviral approach described in this proposal, the engineering of a naturally-occurring nano scale structure, is unique and largely unprecedented. However, given the significant challenges that must be overcome before successful gene therapy can be achieved, a bold new approach is warranted. The vault particle is a highly conserved, abundant and ubiquitous nanocapsule with a large internal capacity to encapsulate and protect labile biological compounds such as nucleic acids. Although the 13 MDa mass of the particle makes it nearly four times the size of the ribosome, the particle is composed of multiple copies of just three proteins and one or more small untranslated RNAs. One of these proteins, MVP, is the major structural protein of the particle. When expressed in insect cells, 96 copies of MVP can assemble into the basic vault capsule. Molecular manipulation of the MVP cDNA allows packaging of specific peptides and proteins into the vault lumen. This proposal outlines a strategy to manipulate the vault nanocapsule so that it can be used to specifically package nucleic acids. In addition, an approach is delineated to modify the particle with cell targeting signals that will allow the specific targeting of these structures to normal or neoplastic cells.
描述(由申请人提供):基因治疗需要经济实惠、可扩展的技术,将感兴趣的基因特异性递送至靶细胞的核区室,而不触发免疫反应。尽管病毒和非病毒载体被设计用于将 DNA 递送至细胞,但人们对非病毒载体的兴趣日益增长,因为它们有望克服操纵病毒所固有的许多限制,包括其复杂性、难以适应大规模生产以及易于触发免疫反应。该提案中描述的非病毒方法,即天然存在的纳米级结构的工程,是独特的,并且在很大程度上是前所未有的。然而,考虑到在成功实现基因治疗之前必须克服的重大挑战,有必要采取大胆的新方法。穹窿颗粒是一种高度保守、丰富且普遍存在的纳米胶囊,具有巨大的内部容量,可以封装和保护核酸等不稳定的生物化合物。尽管该颗粒的质量为 13 MDa,几乎是核糖体大小的四倍,但该颗粒仅由三种蛋白质的多个副本和一种或多种小型非翻译 RNA 组成。这些蛋白质之一,MVP,是颗粒的主要结构蛋白质。当在昆虫细胞中表达时,96 个 MVP 副本可以组装成基本的穹窿胶囊。 MVP cDNA 的分子操作允许将特定的肽和蛋白质包装到穹窿腔中。该提案概述了一种操纵穹窿纳米胶囊的策略,使其可用于特异性包装核酸。此外,还描述了一种用细胞靶向信号修饰颗粒的方法,这将允许这些结构特异性靶向正常或肿瘤细胞。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Vaults are dynamically unconstrained cytoplasmic nanoparticles capable of half vault exchange.
穹窿是动态不受约束的细胞质纳米颗粒,能够进行半穹窿交换。
  • DOI:
    10.1021/nn102051r
  • 发表时间:
    2010
  • 期刊:
  • 影响因子:
    17.1
  • 作者:
    Yang,Jian;Kickhoefer,ValerieA;Ng,BennyC;Gopal,Ajaykumar;Bentolila,LaurentA;John,Scott;Tolbert,SarahH;Rome,LeonardH
  • 通讯作者:
    Rome,LeonardH
Vault nanoparticles engineered with the protein transduction domain, TAT48, enhances cellular uptake.
采用蛋白质转导结构域 TAT48 设计的 Vault 纳米粒子可增强细胞摄取。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LEONARD H ROME其他文献

LEONARD H ROME的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LEONARD H ROME', 18)}}的其他基金

Vault-CCL21 Nanocapsule for Lung Cancer
Vault-CCL21 肺癌纳米胶囊
  • 批准号:
    9321253
  • 财政年份:
    2012
  • 资助金额:
    $ 32.51万
  • 项目类别:
Vault-CCL21 Nanocapsule for Lung Cancer
Vault-CCL21 肺癌纳米胶囊
  • 批准号:
    8698250
  • 财政年份:
    2012
  • 资助金额:
    $ 32.51万
  • 项目类别:
Vaults as Nonviral Nucleic Acid Delivery Vehicles
Vault 作为非病毒核酸递送载体
  • 批准号:
    7184342
  • 财政年份:
    2005
  • 资助金额:
    $ 32.51万
  • 项目类别:
Vaults as Nonviral Nucleic Acid Delivery Vehicles
Vault 作为非病毒核酸递送载体
  • 批准号:
    7055297
  • 财政年份:
    2005
  • 资助金额:
    $ 32.51万
  • 项目类别:
Vaults as Nonviral Nucleic Acid Delivery Vehicles
Vault 作为非病毒核酸递送载体
  • 批准号:
    6861316
  • 财政年份:
    2005
  • 资助金额:
    $ 32.51万
  • 项目类别:
MAGNETIC RESONNANCE CTR:STRUCTURE, FUNCTION OF HIV-1 VPR & HHR23A
磁共振 CTR:HIV-1 VPR 的结构和功能
  • 批准号:
    6794384
  • 财政年份:
    2002
  • 资助金额:
    $ 32.51万
  • 项目类别:
CONSTRUCTION OF MAGNETIC RESONNANCE CENTER
磁共振中心建设
  • 批准号:
    6522046
  • 财政年份:
    2002
  • 资助金额:
    $ 32.51万
  • 项目类别:
MAGNETIC RESONNANCE CTR: PROTEIN STRUCT, TUBERCULOSIS, MOLEC PROBE SYNT
磁共振 CTR:蛋白质结构、结核病、MOLEC 探针合成
  • 批准号:
    6794385
  • 财政年份:
    2002
  • 资助金额:
    $ 32.51万
  • 项目类别:
Consortium for Enhancing Human Subject Research Oversite
加强人类受试者现场研究联盟
  • 批准号:
    6591619
  • 财政年份:
    2002
  • 资助金额:
    $ 32.51万
  • 项目类别:
Consortium for Enhancing Human Subject Research Oversite
加强人类受试者现场研究联盟
  • 批准号:
    6777828
  • 财政年份:
    2002
  • 资助金额:
    $ 32.51万
  • 项目类别:

相似海外基金

Bridging the Gap: Next-Gen Tools for Accurate Prediction of Disordered Protein Binding Sites
弥合差距:准确预测无序蛋白质结合位点的下一代工具
  • 批准号:
    24K15172
  • 财政年份:
    2024
  • 资助金额:
    $ 32.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Design of protein crystal templates with multiple binding sites for tracking metal complex reactions.
设计具有多个结合位点的蛋白质晶体模板,用于跟踪金属络合物反应。
  • 批准号:
    23K04928
  • 财政年份:
    2023
  • 资助金额:
    $ 32.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Dynamic changes in PIP2 binding sites and their impact on axonal targeting and function of epilepsy-associated KCNQ/Kv7 channels
PIP2 结合位点的动态变化及其对癫痫相关 KCNQ/Kv7 通道的轴突靶向和功能的影响
  • 批准号:
    10744934
  • 财政年份:
    2023
  • 资助金额:
    $ 32.51万
  • 项目类别:
Computational methods to identify small molecule RNA binding sites
识别小分子 RNA 结合位点的计算方法
  • 批准号:
    573688-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 32.51万
  • 项目类别:
    University Undergraduate Student Research Awards
Identification of potential drug binding sites within allosteric networks in cyclic nucleotide modulated channels
环核苷酸调节通道变构网络内潜在药物结合位点的鉴定
  • 批准号:
    10704557
  • 财政年份:
    2022
  • 资助金额:
    $ 32.51万
  • 项目类别:
Identification of potential drug binding sites within allosteric networks in cyclic nucleotide modulated channels
环核苷酸调节通道变构网络内潜在药物结合位点的鉴定
  • 批准号:
    10537846
  • 财政年份:
    2022
  • 资助金额:
    $ 32.51万
  • 项目类别:
Identifying new types of inhibitors in quinone binding sites in photosynthetic enzymes
鉴定光合酶醌结合位点的新型抑制剂
  • 批准号:
    2753921
  • 财政年份:
    2022
  • 资助金额:
    $ 32.51万
  • 项目类别:
    Studentship
Development of broad nanovaccines targeting diverse coronavirus receptor-binding sites
开发针对不同冠状病毒受体结合位点的广泛纳米疫苗
  • 批准号:
    10328140
  • 财政年份:
    2022
  • 资助金额:
    $ 32.51万
  • 项目类别:
Exploiting Water Network Perturbations in Protein Binding Sites
利用蛋白质结合位点的水网络扰动
  • 批准号:
    10621368
  • 财政年份:
    2021
  • 资助金额:
    $ 32.51万
  • 项目类别:
SBIR Phase I: Nonlinear optical method for identifying protein-ligand binding sites
SBIR 第一阶段:识别蛋白质-配体结合位点的非线性光学方法
  • 批准号:
    2111821
  • 财政年份:
    2021
  • 资助金额:
    $ 32.51万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了